Immatics Investor Presentation Deck
November 2023, 75 slides
  1. Immatics
  2. Related Decks
  3. Investor Presentation Decks
corporate presentation | Immatics
forward looking statement | Immatics
building a leading therapeutics company | Immatics
upcoming catalysts for and clinical lead assets | Immatics
our based approaches leverage the full target space beyond the cancer cell surface so | Immatics
two distinct based therapeutic modalities in clinical development | Immatics
our pipeline of based adoptive cell therapies and cronies | Immatics
so | Immatics
strategic collaborations so | Immatics
potential for large patient populations across multiple solid cancers so | Immatics
realizing the full cancer opportunity of | Immatics
targeting | Immatics
the cancer opportunity of | Immatics
targeting mechanism of action | Immatics
patient flow so | Immatics
gen melanoma as first indication for pivotal development cohort a | Immatics
| Immatics
trial in advanced solid tumors melanoma patients at total cohort a melanoma patients treated at with gen | Immatics
overview of patient characteristics and responses | Immatics
interim update | Immatics
gen in all melanoma patients at most frequent adverse events so | Immatics
gen across all dose levels tolerability data | Immatics
| Immatics
gen in melanoma targeted to enter registration enabling phase trial in | Immatics
interim update | Immatics
gen leveraging and cells | Immatics
gen preclinical assessment of anti tumor efficacy me | Immatics
gen in cohort most frequent adverse events | Immatics
tolerability data cohort gen | Immatics
gen in cohort bor and response over time | Immatics
gen translational data shows enhanced pharmacology | Immatics
interim update | Immatics
targeting so | Immatics
potential of in additional solid cancer indications | Immatics
targeting development strategy step step step | Immatics
product manufacturing | Immatics
has the potential to reach a large patient population so | Immatics
targeting col a exon | Immatics
first in class targeting tumor stroma | Immatics
high affinity independent | Immatics
our next generation off the shelf | Immatics
cell therapy approach | Immatics
why cells | Immatics
| Immatics
next generation half life extended | Immatics
next generation half life extended | Immatics
potency of our proprietary format | Immatics
format is designed for optimized efficacy and safety | Immatics
format is designed for optimized efficacy and safety | Immatics
our portfolio a | Immatics
targeting so | Immatics
assessment of anti tumor activity in | Immatics
i | Immatics
phase clinical trial to evaluate targeting | Immatics
targeting efficacy assessment in so | Immatics
achieves durable tumor control of large tumors in so | Immatics
half life extended format of terminal half life of week | Immatics
phase clinical trial to evaluate targeting | Immatics
proprietary target and discovery platforms | Immatics
true cancer targets matching right | Immatics
pool of targets as foundation for future value generation | Immatics
unique capability identification of the most relevant target | Immatics
development of the right technology | Immatics
optimal target selection specificity for minimizing safety risks | Immatics
is where the data is | Immatics
robust portfolio | Immatics
corporate information milestones | Immatics
experienced global leadership team across and the us | Immatics
strong focused and highly integrated atlantic organization | Immatics
delivering the power of cells to cancer patients appendix | Immatics
gen in phase a dose bor and response over time | Immatics
gen in cohort a bor and response over time | Immatics
gen in cohort a most frequent adverse events | Immatics
gen at tolerability data | Immatics
delivering the power of cells to cancer patients | Immatics
See More
Immatics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Melanoma
Tumor
Cancer
Monotherapy
Ovarian
Manufacturing
Ovarian cancer
Cell therapy
Solid tumor
Clinical development
Recent decks by Immatics
Results
October 2022
See all presentations by Immatics (2 decks)
Related decks
Alkermes
Investor Day
March 2021
Alkermes
Investor Presentation
October 2023
BioNTech
Results
May 2021
BioNTech
Results
November 2021
Alkermes
Results
June 2022
TScan Therapeutics
IPO
July 2021
BioAtla
Investor Presentation
January 2024
Mink Therapeutics
IPO
October 2021
Recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Alkermes
Investor Day
March 2021
Alkermes
Investor Presentation
October 2023
BioNTech
Results
May 2021
BioNTech
Results
November 2021
Alkermes
Results
June 2022
TScan Therapeutics
IPO
July 2021
BioAtla
Investor Presentation
January 2024
Mink Therapeutics
IPO
October 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io